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Background: Human uterine leiomyoma (fibroids; LYO) are the most common benign neoplasms in
reproductive-aged women. Dysregulated extracellular matrix and irregular LYO reversion-inducing cysteine-rich
protein with Kazal motifs (RECK) expression are thought to be mediated by aberrant microRNA (miR)
expression. The relationship of miR-15b and RECK expression in LYO has not been studied.
Methods: The expression levels of miR-15b and RECK were determined by quantitative RT-PCR, Western blot,
and immunohistochemistry in cultures derived from commercial primary leiomyoma (cpLYO) and myometrial
(cpMYO) cell lines and leiomyoma (pLYO) and myometrium (pMYO) tissue from surgical samples respectively.
The relationship between miR-15b and RECK expression in cpLYO and pLYO (compared to their respective
myometrial controls) was evaluated following transfection of cell cultures with either miR-15b mimic or
inhibitor.
Results: Elevated levels of miR-15b were observed in cpLYO (2.82-fold; p = 0.04) and pLYO cell (1.30-fold; p = 0.0001)
cultures respectively compared to corresponding MYO cell controls. Following transfection with miR-15b mimic, cpLYO
cells (0.62-fold; p < 0.0001) and pLYO cells (0.68-fold; p < 0.0001) demonstrated reduced RECK protein expression.
Following transfection with miR-15b inhibitor, cpLYO cells (1.20-fold; p < 0.0001) and pLYO cells (1.31-fold; p = 0.0007)
demonstrated elevated RECK protein expression. RECK protein expression was reduced in pLYO tissues (0.73-fold; p < 0.
0001) and pLYO (0.47-fold; p = 0.047) cells when compared to the corresponding MYO tissue controls.
Conclusion: Our findings suggest that miR-15b negatively regulates RECK expression in LYO, and increased miR-15b
and decreased RECK expression may contribute to the pathobiology of LYO. The functional significance of miR-15b
and RECK expression warrants further investigation as potential therapeutic targets for the treatment of human LYO.
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Human uterine leiomyoma (fibroids; LYO) are benign
uterine smooth muscle tumors with an estimated overall
incidence of 75 % among reproductive-aged women, and
are symptomatic in approximately 25 % of women [1–3].
This gynecologic disorder may result in heavy and pain-
ful menstrual bleeding, pelvic pressure and pain, recur-
rent pregnancy loss, and infertility. Hysterectomy is the
only curative treatment for this condition, and the effi-
cacy of medical therapy is inconsistent [4]. Fibroids are
the leading indication for hysterectomy, and has been es-
timated to account for an annual healthcare expenditure
of approximately 34 billion dollars [5]. It has been dem-
onstrated that the ovarian steroid hormones, estrogen
(E) and progesterone (P) may play a functional role in
the growth and progression of LYO [6]. However, the
exact mechanisms that contribute to fibroid develop-
ment remain unclear. Genetic alterations, epigenetic
mechanisms (DNA methylation and histone modifica-
tions), growth factors, cytokines, chemokines variations,
and extracellular matrix (ECM) components also have
been identified to be involved in the initiation and devel-
opment of LYO [4, 7, 8]. Recently, differential micro-
RNA (miRNA) expression has been implicated as a
possible contributor to the pathobiology of LYO [9].
MicroRNAs are a class of small noncoding, single-
stranded RNAs, ranging from 19 to 24 nucleotides, and
serve as regulators of targeted gene expression at the post-
transcriptional level [10]. Specifically, miRNAs bind to the
3’-untranslated regions (3’-UTRs) of target mRNAs and
suppress translation from mRNA to relative protein and/
or reduce the stability of mRNA [11, 12]. These noncod-
ing RNAs have been implicated as mediators in several
physiologic and pathologic processes including inflamma-
tion, cell proliferation, differentiation, apoptosis, invasion,
migration, drug resistance and angiogenesis [13, 14]. A
particular miRNA of interest, miR-15b, has been impli-
cated as a mediator of apoptosis by targeting the antiapop-
totic gene bcl2 in gastric cancer cells, mesenchymal stem
cells, and rat hepatic cells [14–16]. Overexpression of
miR-15b has been observed as a modulator of angiogen-
esis, cellular migration, and invasion [13, 17]. Data from
global qPCR array analyses (unpublished, currently under
peer-review) of matched fibroid/myometrium primary tis-
sue from our tissue repository showed that several miR-
NAs species were differentially expressed (upregulated or
downregulated) in fibroids compared to myometrium.
MiR-15b was noted to be upregulated in fibroids com-
pared to myometrium (p < 0.0001). Investigators have also
demonstrated that miR-15b induces apoptosis by targeting
and suppressing Rab1A in human hepatocellular carcin-
oma both in vitro and in vivo [11]. Although, the func-
tional role of miR-15b in tumorigenesis in cancer biology
has been investigated, the role of this miRNA, and itsregulation of gene targets, has not been examined in
uterine fibroids.
Reversion-inducing cysteine-rich protein with Kazal
motifs (RECK) was initially discovered because of its
capacity of inducing reversion in ras-activated fibroblasts
[18]. RECK expression can be ubiquitously detected in
normal adult human tissues, which is required for nor-
mal embryogenesis, vasculogenesis and tissue remodel-
ing [19, 20]. Accumulating evidence has revealed that
RECK has the ability to regulate the angiogenic,
extracellular matrix (ECM) formation, and invasive
and metastatic activities of malignant cells both
in vitro and in vivo [21]. Reduced expression or loss
of RECK expression has been significantly correlated
with poor prognosis in colorectal, breast, lung, pan-
creatic and hepatocellular carcinomas [20–24]. Several
recent studies suggest that miR-15b, miR-16, miR-21,
miR-221, miR-222, miR-372, miR-373, miR-92a and
miR-182 can regulate the expression level of RECK by
targeting its conserved sequences of 3’-UTRs in dif-
ferent diseases [25–27]. The regulation of RECK ex-
pression in uterine fibroids has not been studied
previously and warrants further investigation.
Since miR-15b was upregulated in fibroids in our array
analyses, RECK has been reported to regulate cellular
processes and/or tumorigenesis in cell types other than
uterine fibroids, and miR-15b regulation of RECK in fi-
broids has not been studied, further investigation of this
miR may provide further insight into the pathobiology of
fibroids. The objective of this study was to delineate the
effect of miR-15b on RECK expression in uterine
fibroids and myometrium.
Methods
Patients and tissue collection
Patients undergoing myomectomy or hysterectomy for
uterine fibroids from 2010 through 2013 were recruited
for banking trial and written consent was obtained per
IRB approved protocol (# 2007P000341). A portion of
the intraoperative surgical specimen (uterine fibroid,
matched myometrium, and serum) was collected within
1 h, snap frozen in liquid N2 and stored at −80 °C. Fi-
broids with a size range of 2 to 6 cm in their greatest di-
mension were banked. Matched myometrial sample was
obtained no less than 1 cm from fibroid capsule and
processed in a similar fashion. Following tissue collec-
tion and banking, annotated clinical data was collected
and de-identified. All patients were premenopausal
women in the follicular phase of the menstrual cycle
based on the date of last menstrual period and had not
received any hormonal medications 6 months before
their hysterectomy. Some of the tissue was processed for
RNA and protein extraction, and some was fixed with
4 % paraformaldehyde for immunohistochemistry (IHC)
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pLYO cells and pMYO cells (both referred to as primary
cells in this manuscript).
Cell lines
Human uterine smooth muscle cells (also known as
HUt-SMC [PromoCell, Heidelberg, Germany]),will be
identified as commercial primary myometrial cells,
and abbreviated as cpMYO) were derived from
human myometrium and were grown in smooth
muscle cell growth medium 2 and supplemented with
5 % fetal calf serum (PromoCell), 0.5 % epidermal
growth factor (PromoCell), basic fibroblast growth
factor (PromoCell), and insulin (PromoCell). Human
uterine leiomyoma cells (GM10964, will be identified
as commercial primary leiomyoma cells and abbrevi-
ated as cpLYO) were purchased from Coriell Institute
for Medical Research (Camden, NJ, USA), and were
cultured in Medium 199 (1x) (Gibco, Grand Island,
NY, USA) and 15 % fetal bovine serum (FBS) (Gibco),
heparin (Sigma-Aldrich, St. Louis, MO) and endothe-
lial cell growth supplement (ECGS) (PromoCell). All
cell cultures were incubated in 5 % CO2at 37 °C.
Upon reaching 70–80 % confluence, the cells were
passaged using 0.05 % trypsin-EDTA (Gibco).
Primary cell cultures
Primary leiomyoma (pLYO) cells and primary myometrial
(pMYO) cells were isolated from patient matched LYO
and MYO tissues following the previously described pro-
tocols [28]. Cells were cultured in DMEM/F12 (1:1) (1x)
(Gibco) containing 10 % FBS, 1 % Pen Strep (Gibco) and
0.7 % amphotericin B (Sigma-Aldrich). The cell cultures
were maintained at 37 °C and 5 % CO2. Once the cells
were approximately 70–80 % confluent, they were trypsi-
nized and expanded.
miRNA transfection
Mature mirVana™ miRNA mimic (miRNA-15b mimic),
mirVana™ miRNA inhibitor (miRNA-15b inhibitor), mir-
Vana™ miRNA mimic Negative Control #1 and mirVana™
miRNA inhibitor Negative Control #1 were purchased
from Ambion (Ambion/ThermoFisher Scientific, Grand
Island, NY) and used at a concentration of 10nM/well.
Cells were transfected with either mirVana™ miRNA
mimic negative control #1 or mirVana™ miRNA inhibitor
negative control #1 at all data points. Cells were plated
at a density of 1 × 105 cells/well in 12 well plates. The
transfection was conducted using LipofectamineTMRNAi
MAX (Invitrogen/Thermo Scientific) on the following
day according to the manufacturer’s protocol. RNA/pro-
tein was extracted from the cells for quantitative RT-
PCR (qRT-PCR) and Western blot assays at the indi-
cated time points post transfection.RNA isolation and quantitative RT-PCR assay
Total RNA was extracted from cultured cells and human
tissue with mirVana miRNA Isolation kit (Ambion/Ther-
moFisher Scientific) in accordance with the manufactur-
er's protocol. The quantity and quality of the isolated
RNAs were assessed using the ND-1000 Spectrophotom-
eter (NanoDrop Technologies, Wilmington, DE). To
evaluate the expression level of miR-15b in tissues and
cells, cDNA was prepared with Universal cDNA Synthe-
sis Kit II (Exiqon, Woburn, MA, USA) according to the
manufacturer’s instructions. qRT-PCR was performed in
a total volume of 20 μL, containing 100 ng cDNA, hsa-
miR-15b LNA™ PCR primer (Exiqon) and ExiLENT
SYBR® Green master mix (Exiqon) on Bio-Rad's QX100™
Droplet Digital™ PCR System (Bio-Rad Laboratories,
Munich, Germany). MiR-30c was employed as the
internal control. For RECK mRNA expression determin-
ation in tissues and cultured cells, cDNA was synthe-
sized using SuperScript® VILO™ cDNA Synthesis Kit
(Invitrogen/ThermoScientific). QRT-PCR was carried
out on the Bio-Rad's QX100™ Droplet Digital™ PCR Sys-
tem using SsoAdvanced™ universal SYBR® Green super-
mix (Bio-Rad Laboratories, Munich, Germany) and the
following primers (Invitrogen/ThermoScientific): RECK
sense 5’-tccatctggagatccctgtc-3’ and anti-sense 5’-tgccag-
caaaacaagaacag-3’. Actin was applied as the internal con-
trol. All reactions were incubated at 95 °C for 10 min as
initial denaturation followed by 40 cycles of 95 °C for
15 s and 60 °C for 1 min. The relative expression level of
miRNA-15 band RECK was analyzed with the compara-
tive cycle threshold method (2-ΔΔCT). Preparations lack-
ing RNA were used in place of the cDNA and applied as
a negative control. All reactions were performed in
triplicate.
Western blot analysis
Protein was extracted with 1X RIPA lysis buffer (Upstate
Biotechnology, Charlottesville, VA, USA), 1 mM PMSF
(Sigma, St. Louis, MO, USA) and a protease inhibitor
cocktail (Sigma) from cultured cells and tissues. The
protein content was evaluated using the DC Protein
Assay (Bio-Rad Laboratories, Munich, Germany) and
using bovine serum albumin (BSA) as the standard.
Equal amounts of total protein were boiled and sepa-
rated on NuPAGE® 4–12 % Bis-Tris Gel (Life Technolo-
gies, Carlsbad, CA, USA) and then transferred onto a
PVDF membrane (Bio-Rad). The membranes were
blocked by incubating in Tris-buffered saline and
Tween-20 (TBST) containing 5 % skim dry milk for 2 h
before incubation with rabbit monoclonal antibody
against human RECK (Cell Signaling Technology,
Beverly, MA, USA) at the dilution of 1:1000 and mouse
anti-human β-actin monoclonal antibody (Cell Signaling
Technology) at the dilution of 1:1000 at 4 °C overnight.
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probed with respective secondary antibodies (horserad-
ish peroxidase-conjugated goat anti-rabbit or anti-mouse
IgG (Santa Cruz Biotechnology, Inc, Santa Cruz, CA,
USA) diluted 1:10000 for 1 h at room temperature. The
protein band signals were detected by using an Amer-
sham™ ECL™ PrimeWestern blotting detection reagent
(GE Healthcare, UK) after rinsing membranes with
TBST 3 times according to the manufacturer’s instruc-
tions. The strips were finally scanned with ChemiDocTM
XRS+ imaging System (Bio-Rad Laboratories). Quantifi-
cation of bands intensities was conducted via Image J
software (National Institute of Health, Bethesda, MD,
USA).
Immunohistochemical staining
Immunohistochemistry (IHC) was conducted in leio-
myoma and matched myometrial tissues by following
the manufacturer’s guidelines to assess the expression
level of RECK. In brief, 5-μm paraffin tissue section
slides were baked in a drying oven, deparaffinized and
hydrated through xylene and graded alcohol. Antigens
were retrieved by boiling slides in unmasking solution
(Dako Corporation, Carpinteria, CA, USA), and
endogenous peroxidase activity was quenched by
incubation in 3 % H2O2 for 10 min. To reduce
nonspecific background staining, the slides were
allowed to block with 5 % normal goat serum in PBS
with 0.1 % Triton X for 1 h at room temperature.
Subsequently, they were incubated with primary anti-
body (dilution: 1:50) in a humidified chamber at 4 °C
overnight. The signal was detected using 3,3′-diami-
nobenzidine (DAB) chromogen (Dako Corporation).
Prior to recording images, the slides were counter-
stained with Hematoxylin QS (Vector Laboratories,
Burlingame, CA, USA), dehydrated with xylene, and
mounted with VectaMount AQ (Vector Laboratories)
for long-term preservation. Immunohistochemistry
staining intensity was graded on a semi quantitative
scale from 0 to 4 (0 indicates none; 1, weak; 2,
intermediate; 3, strong; 4, extremely strong). Two
independent investigators determined the staining
intensity of positive RECK stained cells in 3 random
fields per tissue section in a blinded manner.
Statistical analysis
Statistical analysis was undertaken using GraphPad
Prism 5 software (GraphPad Software, Inc., La Jolla,
CA). Collected data were presented as the mean ± SD.
Student’s two-tailed t-test, Mann–Whitney U test, or
chi-square (χ2) test was applied appropriately to identify
the statistical significance of observed differences
between groups. In all tests, a value of p < 0.05 was
considered significant.Results
Increased expression of miR-15b in human LYO
MiR-15b was observed to be differentially expressed be-
tween human leiomyoma and matched myometrial tis-
sues in our miRNA microarray analysis (unpublished
data). To confirm the preliminary results of miRNA
microarray analysis, we compared miR-15b expression
level in cells and tissues from leiomyoma and myome-
trial cells/tissues by qRT-PCR. Similar to the large scale
miRNA microarray data, miR-15b expression was
greater (3.95-fold; p < 0.0001) in pLYO tissues compared
to paired pMYO tissues (Fig. 1a). Moreover, miR-15b
was increased in cpLYO cell line (2.82-fold; p = 0.04,
Fig. 1b) and pLYO cells (1.3-fold; p < 0.0001, Fig. 1c)
when compared with their MYO cell controls,
respectively.
RECK is a potential target of miR-15b
Following transfection of cpLYO cell line, cpMYO cell
line, pLYO cells and pMYO cells with miR-15b
mimic, miR-15b expression was increased (p < 0.0001)
by 2903.23, 5248.42, 1320.35 and 1607.57-fold 24 h in
cpLYO cell line, cpMYO cell line, pLYO cells and
pMYO cells, respectively (Fig. 2a). Following transfec-
tion with miR-15b inhibitor, miR-15b expression was
reduced (p < 0.0001) by 0.62, 0.25, 0.20 and 0.64-fold
at 24 h in cpLYO and cpMYO cell lines, pLYO cells
and pMYO cells, respectively (Fig. 2c). Similar results
were observed in miR-15b mimic and inhibitor
treated cells respectively 48 h after transfection
(Fig. 2b and d).
To provide additional evidence that miR-15b may
regulate RECK mRNA, the expression level of RECK
mRNA was evaluated in miR-15b mimic transfected
cells. RECK mRNA expression decreased in cpLYO cells
(0.78-fold; p =0.03), cpMYO cells (0.33-fold; p < 0.0001),
pLYO cells (0.90-fold; p = 0.27) and pMYO cells (1.07-
fold, p = 0.96) respectively 24 h after miR-15b mimic
transfection. Similarly, at 48 h post transfection, the
RECK mRNA expression declined 0.59-fold (p = 0.003),
0.35-fold (p < 0.0001), 0.62-fold (p < 0.0001), and 0.89-
fold (p = 0.22) in miR-15b mimic transfected cpLYO
cells, cpMYO cells, pLYO cells and pMYO cells, respect-
ively, when compared with cells without treatment
(Fig. 3a and b).
The expression level of RECK is decreased in primary
leiomyoma tissues and cells
We assessed the RECK protein expression in LYO and
MYO tissues and primary cultured cells in the absence
of mimics or inhibitors to determine base line compari-
sons of RECK protein in patient matched samples.
Lower RECK protein expression was observed in pLYO
tissues (0.73-fold; p < 0.0001) and pLYO cells (0.47-fold,
Fig. 1 miR-15b expression is up-regulated in uterine leiomyoma tissue and cultured cells. a Comparison of miR-15b expression level between
isolated pLYO tissue and paired pMYO tissue. b Expression level of miR-15b in cpLYO cells as well as cpMYO cells. c Comparison of miR-15b level
between pLYO cells and pMYO cells. Quantitative RT-PCR assay was performed as described in the methods section. All data were presented as
mean ± SD and analyzed using Student’s t-test (two tail, unequal variance) and Mann–Whitney U test applicable. The experiments were performed
in triplicate. Statistical significance was noted as * p < 0.05, ** p < 0.005, *** p < 0.001
Fig. 2 miR-15b mimic and inhibitor delivery into LYO and MYO cells via transient transfection. a Relative miR-15b expression in miR-15b
mimic transfected cells 24 h post transfection. b Relative expression level of miR-15b in cells 48 h after miR-15b mimic transfection. c
Influence of miR-15b inhibitor on miR-15b expression in cells 24 h after transfection. d Relative miR-15b expression in miR-15b inhibitor
transfected cells 48 h post transfection. Cells without miR-15b mimic or miR-15b inhibitor transfection were used as control group, which
was abbreviated as cell blank. Quantitative RT-PCR experiment was performed as described in methods. The data were presented as
mean ± SD and analyzed using Student’s t-test (two tail, unequal variance) and Mann–Whitney U test appropriately. The experiments were
conducted in triplicate. Statistical significance was noted as *** p < 0.001
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Fig. 3 Inhibition of RECK mRNA expression by transfection miR-15b mimic in different type of cells. a qRT-PCR demonstrating decreased expres-
sion of RECK mRNA in cpLYO and cpMYO cells at 24 h post transfection with miR-15b mimic. b Reduction of RECK mRNA observed in miRNA-
15b mimic transfected cpLYO, cpMYO and pLYO cells 48 h post transfection. Cells without miR-15b mimic transfection were used as control
group, which was abbreviated as cell blank. Quantitative RT-PCR assay was performed as described in methods section. All data were presented
as mean ± SD and analyzed using Student’s t-test (two tail, unequal variance) and Mann–Whitney U test when applicable. The experiments were
performed in triplicate. Statistical significance was noted as* p < 0.05, ** p < 0.005, *** p < 0.001
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pMYO cells, respectively (Fig. 4a and b). The relative
RECK protein expression level was quantified by densi-
tometry and the results were also shown in Fig. 4a and
b. Immunohistochemistry was then carried out to
further evaluate the expression level of RECK protein in
tissue sections collected from pLYO and matched
pMYO. Both cytoplasmic and nuclear immunoreactivityFig. 4 Differential expression level of RECK in pLYO and pMYO paired tissues
tissues as determined by Western blot analysis. b Western blot analysis of REC
Representative matched pLYO and pMYO immunostained for RECK. The distr
matched pLYO and pMYO tissue. Magnification: 10 × (left panel) and 40 × (righ
RECK immunohistochemical staining scores in matched LYO and MYO tissues
Student’s t-test (two tail, unequal variance), Mann–Whitney U test and chi-squ
** p < 0.005, *** p < 0.001of RECK was observed, and specific RECK protein stain-
ing was primarily localized in cell cytoplasm. The immu-
nostaining of RECK was visually less in the pLYO group
compared with that in the matched pMYO group
(Fig. 4c). The immunostaining intensities of RECK were
assessed, and decreased RECK positive cells were ob-
served in LYO tissues as compared with that in matched
control specimens (0.47-fold; p = 0.04; Fig. 4c).and isolated cells. a RECK expression level in matched pLYO and pMYO
K in pLYO and pMYO cell cultures from patient matched samples. c
ibution of RECK immunohistochemical staining of paraffin sections from
t panel); Arrows indicated positive expression of RECK. Distribution of
were also showed. Data represented as Mean ± SD and analyzed using
are (χ2) test appropriately. Statistical significance was noted as * p < 0.05,
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getScan, PicTar, and miRanda, http://www.targetscan.org;
http://pictar.mdc-berlin.de/ and http://www.microrna.org/
were adopted to identify the potential target genes of miR-
15b. Among these genes, RECK was selected as the candi-
date for further analysis since miR-15b can bind to the 3’-
UTR of RECK. It has been predicted that miR-15b shared
8 identical nucleotides of the 5’ “seed” region that are
complementary to bases 811–813 of the RECK 3’-UTR
(Fig. 5a), and therefore it may potentially target RECK by
in silico analysis [26]. To ascertain whether miR-15b
modulate RECK expression, the cells were transfected
with either specific miR-15b mimic or inhibitor at a final
concentration of 10 nM for 48 h to increase or reduce en-
dogenous miR-15b expression in both cell lines and cul-
tured primary cells. A lower (0.62-fold; p < 0.0001) levels
of RECK protein was observed in miR-15b mimic trans-
fected cpLYO cells compared to mimic control transfectedFig. 5 miR-15b is predicted to bind to the 3’-UTR of RECK and regulate
miR-15b in the 3’-UTR of RECK. RECK mRNA has the potential complim
regulation of RECK protein expression in cpLYO cells. Proteins from cpL
nM. After 48 h, the lysates were analyzed by Western blot. c miR-15b
regulation of RECK protein expression in pLYO cells. e miR-15b regulat
as means ± SD. Statistical comparisons between miR-15b mimic/inhibito
analyzed using Student’s t-test (two tail, unequal variance) and Mann–W
*p < 0.05, **p < 0.005, ***p < 0.001cells, while miR-15b knockdown by miR-15 inhibitor
transfection resulted in increased (1.20-fold; p < 0.0001)
RECK expression as determined by Western blot analysis
(Fig. 5b). Lower (0.85-fold; p < 0.0001) levels of RECK pro-
tein was observed in miR-15b mimic transfected cpMYO
cells compared to mimic control transfected cells, while
miR-15b knockdown by miR-15 inhibitor transfection re-
sulted in increased (1.22-fold; p = 0.003) (Fig. 5c). Similar
results were exhibited in pLYO cells with miR-15b mimic
transfection (0.68-fold; p < 0.0001) and inhibitor transfec-
tion (1.31-fold; p = 0.0007) (Fig. 5d). Similar results were
found in pMYO cells by transfecting miR-15b mimic
(0.70-fold; p = 0.02) and by transfecting miR-15b inhibitor
(1.53-fold; p = 0.02) (Fig. 5e).
Discussion
In the current study, we investigated the expression pat-
terns of miR-15b and RECK in cultured primary LYOs RECK expression. a Scheme of the potential binding sites of
entary binding site with miR-15b within its 3’-UTR. b miR-15b
YO cells transfected with either miR-15b mimic or inhibitor at 10
regulation of RECK protein expression in cpMYO cells. d miR-15b
ion of RECK protein expression in pMYO cells. Data were presented
r transfected cells and mimic/inhibitor negative control cells was
hitney U test appropriately. Statistical significance was noted as
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primary LYO and MYO cells and tissue derived from
hysterectomy samples from our patient population. Our
findings demonstrate that miR-15b expression is ele-
vated in leiomyoma compared to the myometrium. Con-
versely, RECK expression is lower in LYO tissues and
cultured LYO cells (commercial and primary sources)
when compared to myometrial controls. The inverse re-
lationship in expression between miR-15b and RECK
was also observed during transfection studies which
overexpressed and inhibited miR-15b via mimics or
antagomirs, respectively. To our knowledge, this is the
first study to begin to delineate the possible functional
significance of miR-15b as a regulator of RECK expres-
sion in fibroids.
MiR-15b is a member of the miR-15/16 superfamily,
which possesses a 5’-end AGCAGC sequence, and in-
cludes miR-15a, miR-15b, miR-16, miR-195, miR-322,
miR-497 among others. Overexpression of miR-15b has
been correlated with poor prognosis and tumorigenesis.
Several investigators have implied that miR-15b is a pos-
sible prognostic molecular marker and potential thera-
peutic target in cancer biology [23, 29]. Recent studies
have reported overexpression of miR-15b exhibited in
cells lines of human hepatocellular carcinoma, pancre-
atic cancer, acute promyelocytic leukemia, cervical can-
cer and malignant melanoma when compared to cell
lines derived from benign tissue [11, 30, 31]. Marked up-
regulation in miR-15b expression was demonstrated to
regulate the expression of targeted bcl-2, cyclin E1,
Rab1A, NRP-2, MMP-3 and VEGFR-2, and therefore
modulate numerous cellular biological processes, such
as cell proliferation, division, apoptosis, migration, inva-
sion, metabolism, stress, angiogenesis and drug resist-
ance [11, 13–15, 23, 32, 33].
Previous studies have reported global miRNA expres-
sion patterns in paired sets of LYO and MYO tissue,
and have described several differentially expressed miR-
NAs, including miR-15b. Unfortunately, the results of
some studies are inconsistent with regards to the rela-
tive expression of miR-15b in LYO tissue compared to
MYO tissue [9, 29, 34–37]. An analysis consisting of
213 human miRNAs probes identified that lower ex-
pression level of miR-15b was exhibited in leiomyomas
as compared to their paired myometrium. However,
expression levels of miR-15b were not different among
matched isolated myometrial (MSMC) and leiomyoma
(LSMC) smooth muscle cells, spontaneously trans-
formed LSMC (t-LSMC) and a leiomyosarcoma cell line
(SKLMS-1) [9, 35]. Applying comparative genomic
hybridization analysis in 8 LYO of black women, it was
demonstrated that miR-15b was lost in two of the 8
women [34]. In two other studies, differential expres-
sion of miR-15b was not shown in human LYO versusMYO in a microarray analysis containing of 454
miRNA species and one consisting of 206 human
miRNAs [29, 36]. Moreover, Boryana Georgieva et al.
used next-generation sequencing approaches and
bioinformatics methods to determine the aberrant
expressed miRNAs in LYO and MYO, and did not
observe differential miR-15b expression [37]. In con-
trast to previous studies, we observed higher expres-
sion of miR-15b in LYO than their corresponding
MYO controls following microarray and qRT-PCR.
Possible explanations for variable results may be due
to different techniques of miRNA analyses, which
may include a wide range of array analyses with or
without PCR validation of findings. From a demo-
graphic standpoint, differential genetics, and race/eth-
nicity of patients, fibroid sizes, inconsistent specimen
processing techniques (from surgical sample) and
intrinsic biologic variability may also contribute to
variable results among studies.
Based on available bioinformatic algorithms that pre-
dict targets, RECK may be a target of miR-15b. Interest-
ingly, a recent report also revealed that miR-15b holds
the ability to negatively modulate targeted RECK in the
HT1080 human fibrosarcoma cell line and Caco-2, a
colon carcinoma cell line [26]. To our knowledge, the
expression pattern of RECK had not been well estab-
lished in human LYO relative to myometrium. This led
us to explore this relationship. We demonstrated that
RECK is expressed at lower level in LYO tissues than
myometrial tissues as determined by Western blot and
IHC. We also extend this observation to show that re-
duced relative levels of RECK expression was present in
primary LYO cells as compared to primary MYO cells in
this study. Our data further support this inverse relation-
ship as evidenced in LYO and MYO cell cultures (both
commercial and derived from primary tissue samples)
following transfection of either miR-15b mimic or miR-
15b inhibitor to either overexpress or inhibit miR-15b
expression. The addition of miR-15 mimics resulted in
decreased RECK. Likewise, transfection with miR-15b
antagomirs increased RECK expression. These data
provide evidence to suggest that miR-15b by indirect or
direct interaction can regulate RECK expression.
RECK, a recently characterized membrane bound pro-
tein, has been identified to play a pivotal role in cancer
progression by limiting invasion, metastasis and angio-
genesis of tumors [19–21, 38, 39]. A large number of
tumor cell lines and tissues including colorectal, breast,
pancreatic, gastric cancer have low or undetectable
RECK expression, [19, 25]. For example, decreased
RECK expression has been reported in 81.8 % of 11 gas-
tric cancer cell lines and 52 % of the 102 gastric cancer
tissues [40]. Furthermore, accumulated evidence amply
supports that RECK holds the potential value as a
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[22, 24, 38, 40–43]. Pancreatic cancer patients with
higher RECK expression showed statistical better prog-
nosis as compared to that with negative RECK expres-
sion [22]. Likewise, a study conducted in a cohort of 283
colorectal cancer patients implied that reduced RECK
expression was an independent prognostic biomarker of
poor survival [24]. There is also an obvious inverse cor-
relation between RECK expression and macroscopic
tumor growth, lymphatic invasion, lymph node metasta-
sis as well as stage, which suggests that RECK consti-
tutes a good prognostic marker in gastric cancer [40].
Therefore, if there were elevated levels of miR-15b in
leiomyoma it may well down regulate the anti-tumor
effects of RECK. Future studies which induce long-term
over and under-expression of miR 15-b via lentiviral
infection of a mimic and antagomir in fibroids and myo-
metrium primary cell culture and immortalized cultures
will be necessary to evaluate the possible anti-tumor ef-
fects of RECK by evaluating cell proliferation and the
cell cycle transition via flow cytometry.
From another perspective, the most distinct character-
istic of LYO is the excessive deposition of ECM and
synthesis of ECM proteins, such as MMP-2, MMP-9,
MMP-11 [44, 45]. MicroRNA-15 was previously
reported to inhibit the expressions of MMP-2, MMP-9
and MMP-14 which involves in breaking down the ECM
[46–49]. We therefore speculate that with increased
miR-15b and reduced RECK expression, there may be
reduced RECK mediated inhibition of ECM proteins
synthesis, aberrant ECM production and an increased
potential for LYO development. Whether miR-15b has
the capacity to specifically regulate the breakdown of
ECM or be involved in other cellular functional activ-
ities, such as apoptosis, angiogenesis, migration and
invasion, in human LYO is yet to be determined. Future
studies will be necessary to investigate if miR-15b over-
expression in fibroid and myometrium studies result in
upregulation of the fibroid relevant MMP, 2, 9, and 11
and increase production of type 1 and 3 fibrillar colla-
gens, which are characteristic of the signature aberrant
ECM production in this gynecologic disorder.
Conclusion
Our findings demonstrate that overexpression of miR-
15b results in concurrent decreased RECK expression in
human LYO, and suggests that miR-15b may target
RECK in LYO. Collectively, our results provide further
insight into potential mechanisms for miR mediated
regulation of fibroid development and/or progression
and warrants further investigation.
Acknowledgments
Not applicable.Funding
This work was supported, in part, by the Vincent Memorial Research Funds.
Dr. Guan was supported by grants from the Scientific and Technological
Project of Henan Province (NO. 201203049). Support was provided in part by
the Merck Serono China Research Fund for Fertility. All funding supported, in
part, the efforts of authors in conducting experiments and data collection.
Availability of data and materials
Readily reproducible material/data available upon request.
Authors’ contributions
YG, BRR, and AKS conceived and designed the study. YG, LG, LZ, BRR, and
AKS performed all experiments. YG, BRR, and AKS analyzed, interpreted data
and wrote the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent
This study was approved by the Partners Healthcare Institutional Review
Board (Protocol # 2012P001680).
Author details
1Center for Reproductive Medicine, The Third Affiliated Hospital of
Zhengzhou University, Zhengzhou 450052, Henan Province, China. 2Vincent
Department of Obstetrics and Gynecology, Vincent Center for Reproductive
Biology, Massachusetts General Hospital, Their 9, 55 Fruit Street, Boston, MA
02114, USA. 3Department of Pathology, Massachusetts General Hospital,
Boston, MA 02114, USA. 4Departments of Obstetrics, Gynecology, and
Reproductive Biology, Harvard Medical School, Boston, MA 02115, USA.
Received: 3 March 2016 Accepted: 4 August 2016
References
1. Mehine M, Kaasinen E, Makinen N, Katainen R, Kampjarvi K, Pitkanen E, et al.
Characterization of uterine leiomyomas by whole-genome sequencing.
N Engl J Med. 2013;369:43–53.
2. Fitzgerald JB, Chennathukuzhi V, Koohestani F, Nowak RA, Christenson LK.
Role of microRNA-21 and programmed cell death 4 in the pathogenesis of
human uterine leiomyomas. Fertil Steril. 2012;98:726–34. e2.
3. Eltoukhi HM, Modi MN, Weston M, Armstrong AY, Stewart EA. The health
disparities of uterine fibroid tumors for African American women: a public
health issue. Am J Obstet Gynecol. 2014;210:194–9.
4. Commandeur AE, Styer AK, Teixeira JM. Epidemiological and genetic clues
for molecular mechanisms involved in uterine leiomyoma development and
growth. Hum Reprod Update. 2015;21:593–615.
5. Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The
estimated annual cost of uterine leiomyomata in the United States. Am J
Obstet Gynecol. 2012;206:211 e1–9.
6. Reis FM, Bloise E, Ortiga-Carvalho TM. Hormones and pathogenesis of
uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016;34:13–24.
7. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine
leiomyomas: a review. Environ Health Perspect. 2003;111:1037–54.
8. Islam MS, Protic O, Stortoni P, Grechi G, Lamanna P, Petraglia F, et al.
Complex networks of multiple factors in the pathogenesis of uterine
leiomyoma. Fertil Steril. 2013;100:178–93.
9. Karmon AE, Cardozo ER, Rueda BR, Styer AK. MicroRNAs in the development
and pathobiology of uterine leiomyomata: does evidence support future
strategies for clinical intervention? Hum Reprod Update. 2014;20:670–87.
10. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the
implications for cancer research. Nat Rev Cancer. 2010;10:389–402.
11. Yang Y, Hou N, Wang X, Wang L, Chang S, He K, et al. miR-15b-5p induces
endoplasmic reticulum stress and apoptosis in human hepatocellular
carcinoma, both in vitro and in vivo, by suppressing Rab1A. Oncotarget.
2015;6:16227–38.
Guan et al. Reproductive Biology and Endocrinology  (2016) 14:45 Page 10 of 1012. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight? Nat Rev
Genet. 2008;9:102–14.
13. Zheng X, Chopp M, Lu Y, Buller B, Jiang F. MiR-15b and miR-152 reduce
glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Lett.
2013;329:146–54.
14. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, et al. miR-15b and miR-16
modulate multidrug resistance by targeting BCL2 in human gastric cancer
cells. Int J Cancer. 2008;123:372–9.
15. Guo CJ, Pan Q, Li DG, Sun H, Liu BW. miR-15b and miR-16 are implicated in
activation of the rat hepatic stellate cell: An essential role for apoptosis.
J Hepatol. 2009;50:766–78.
16. Yu B, Gong M, He Z, Wang YG, Millard RW, Ashraf M, et al. Enhanced
mesenchymal stem cell survival induced by GATA-4 overexpression is
partially mediated by regulation of the miR-15 family. Int J Biochem Cell
Biol. 2013;45:2724–35.
17. Chan LS, Yue PY, Wong YY, Wong RN. MicroRNA-15b contributes to
ginsenoside-Rg1-induced angiogenesis through increased expression of
VEGFR-2. Biochem Pharmacol. 2013;86:392–400.
18. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, et al.
Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion
by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A.
1998;95:13221–6.
19. Clark JC, Thomas DM, Choong PF, Dass CR. RECK–a newly discovered
inhibitor of metastasis with prognostic significance in multiple forms of
cancer. Cancer Metastasis Rev. 2007;26:675–83.
20. Meng N, Li Y, Zhang H, Sun XF. RECK, a novel matrix metalloproteinase
regulator. Histol Histopathol. 2008;23:1003–10.
21. Alexius-Lindgren M, Andersson E, Lindstedt I, Engstrom W. The RECK gene
and biological malignancy–its significance in angiogenesis and inhibition of
matrix metalloproteinases. Anticancer Res. 2014;34:3867–73.
22. Masui T, Doi R, Koshiba T, Fujimoto K, Tsuji S, Nakajima S, et al. RECK
expression in pancreatic cancer: its correlation with lower invasiveness and
better prognosis. Clin Cancer Res. 2003;9:1779–84.
23. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, et al. The
membrane-anchored MMP inhibitor RECK is a key regulator of extracellular
matrix integrity and angiogenesis. Cell. 2001;107:789–800.
24. Stenzinger A, von Winterfeld M, Rabien A, Warth A, Kamphues C, Dietel M,
et al. Reversion-inducing cysteine-rich protein with Kazal motif (RECK)
expression: an independent prognostic marker of survival in colorectal
cancer. Hum Pathol. 2012;43:1314–21.
25. Chen Y, Tseng SH. The potential of RECK inducers as antitumor agents for
glioma. Anticancer Res. 2012;32:2991–8.
26. Loayza-Puch F, Yoshida Y, Matsuzaki T, Takahashi C, Kitayama H, Noda M.
Hypoxia and RAS-signaling pathways converge on, and cooperatively
downregulate, the RECK tumor-suppressor protein through microRNAs.
Oncogene. 2010;29:2638–48.
27. Lin HY, Chiang CH, Hung WC. STAT3 upregulates miR-92a to inhibit RECK
expression and to promote invasiveness of lung cancer cells. Br J Cancer.
2013;109:731–8.
28. Chang HL, Senaratne TN, Zhang L, Szotek PP, Stewart E, Dombkowski D,
et al. Uterine leiomyomas exhibit fewer stem/progenitor cell characteristics
when compared with corresponding normal myometrium. Reprod Sci.
2010;17:158–67.
29. Wang T, Zhang X, Obijuru L, Laser J, Aris V, Lee P, et al. A micro-RNA
signature associated with race, tumor size, and target gene activity in
human uterine leiomyomas. Genes Chromosomes Cancer. 2007;46:336–47.
30. Satzger I, Mattern A, Kuettler U, Weinspach D, Voelker B, Kapp A, et al.
MicroRNA-15b represents an independent prognostic parameter and is
correlated with tumor cell proliferation and apoptosis in malignant
melanoma. Int J Cancer. 2010;126:2553–62.
31. Finnerty JR, Wang WX, Hebert SS, Wilfred BR, Mao G, Nelson PT. The miR-
15/107 group of microRNA genes: evolutionary biology, cellular functions,
and roles in human diseases. J Mol Biol. 2010;402:491–509.
32. Vimalraj S, Selvamurugan N. Regulation of proliferation and apoptosis in
human osteoblastic cells by microRNA-15b. Int J Biol Macromol. 2015;79:490–7.
33. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, et al. Aberrant expression
of oncogenic and tumor-suppressive microRNAs in cervical cancer is
required for cancer cell growth. PLoS One. 2008;3:e2557.34. Zavadil J, Ye H, Liu Z, Wu J, Lee P, Hernando E, et al. Profiling and functional
analyses of microRNAs and their target gene products in human uterine
leiomyomas. PLoS One. 2010;5:e12362.
35. Pan Q, Luo X, Chegini N. Differential expression of microRNAs in
myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol
Med. 2008;12:227–40.
36. Marsh EE, Lin Z, Yin P, Milad M, Chakravarti D, Bulun SE. Differential
expression of microRNA species in human uterine leiomyoma versus
normal myometrium. Fertil Steril. 2008;89:1771–6.
37. Georgieva B, Milev I, Minkov I, Dimitrova I, Bradford AP, Baev V.
Characterization of the uterine leiomyoma microRNAome by deep
sequencing. Genomics. 2012;99:275–81.
38. Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, Koyama F, et al. The
membrane-anchored matrix metalloproteinase (MMP) regulator RECK in
combination with MMP-9 serves as an informative prognostic indicator for
colorectal cancer. Clin Cancer Res. 2004;10:5572–9.
39. Sasahara RM, Brochado SM, Takahashi C, Oh J, Maria-Engler SS, Granjeiro JM,
et al. Transcriptional control of the RECK metastasis/angiogenesis suppressor
gene. Cancer Detect Prev. 2002;26:435–43.
40. Song SY, Son HJ, Nam E, Rhee JC, Park C. Expression of reversion-inducing-
cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in
gastric cancer. Eur J Cancer. 2006;42:101–8.
41. Takenaka K, Ishikawa S, Kawano Y, Yanagihara K, Miyahara R, Otake Y, et al.
Expression of a novel matrix metalloproteinase regulator, RECK, and its
clinical significance in resected non-small cell lung cancer. Eur J Cancer.
2004;40:1617–23.
42. Span PN, Sweep CG, Manders P, Beex LV, Leppert D, Lindberg RL. Matrix
metalloproteinase inhibitor reversion-inducing cysteine-rich protein with
Kazal motifs: a prognostic marker for good clinical outcome in human
breast carcinoma. Cancer. 2003;97:2710–5.
43. van der Jagt MF, Sweep FC, Waas ET, Hendriks T, Ruers TJ, Merry AH, et al.
Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK)
and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2,
MMP-9, and survival in colorectal cancer. Cancer Lett. 2006;237:289–97.
44. Halder SK, Osteen KG, Al-Hendy A. Vitamin D3 inhibits expression and
activities of matrix metalloproteinase-2 and −9 in human uterine fibroid
cells. Hum Reprod. 2013;28:2407–16.
45. Koohestani F, Braundmeier AG, Mahdian A, Seo J, Bi J, Nowak RA.
Extracellular matrix collagen alters cell proliferation and cell cycle
progression of human uterine leiomyoma smooth muscle cells. PLoS One.
2013;8:e75844.
46. Qin J, Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and
metastasis by targeting RECK. FEBS Lett. 2014;588:99–104.
47. Xin C, Buhe B, Hongting L, Chuanmin Y, Xiwei H, Hong Z, et al. MicroRNA-
15a promotes neuroblastoma migration by targeting reversion-inducing
cysteine-rich protein with Kazal motifs (RECK) and regulating matrix
metalloproteinase-9 expression. FEBS J. 2013;280:855–66.
48. Chiang CH, Hou MF, Hung WC. Up-regulation of miR-182 by beta-
catenin in breast cancer increases tumorigenicity and invasiveness by
targeting the matrix metalloproteinase inhibitor RECK. Biochim Biophys
Acta. 1830;2013:3067–76.
49. Takagi S, Simizu S, Osada H. RECK negatively regulates matrix
metalloproteinase-9 transcription. Cancer Res. 2009;69:1502–8.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
